🔗 Permalink

Inventor profile of:

JOHN BELL

City:

OTTAWA

Country:

Canada

Published Applications:

18

Last publication date:

2024-07-25

Top Assignees for applications by JOHN BELL

The entities that hold a legal rights for patent applications filed by inventor BELL JOHN:

SILLAJEN BIOTHERAPEUTICS, INC. 5 San Francisco, CA United States
TURNSTONE LIMITED PARTNERSHIP 4 TORONTO, Canada
OTTAWA HOSPITAL RESEARCH INSTITUTE 3 Ottawa, Canada
JENNEREX, INC. 2 San Francisco, CA United States
SILLAJEN, INC. 2 Busan, South Korea
Avaya Inc 1 Basking Ridge, NJ United States
Ottawa Hospital Research Institute 1 Ottawa, Ontario, Canada
Children's Hospital Eastern Ontario Research Institute Inc. 1 Ottawa, Canada
TURNSTONE LIMITED PATNERSHIP 1 Toronto, Canada
Ottawa Hospital Research Institute 1 Ontario, Canada
NORTEL NETWORKS LIMITED 1 Quebec, Canada

Recent patent applications by BELL JOHN

JOHN BELL from OTTAWA, CA has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-07-25

US20240245804A1

Human necessities

Expression of Bacterial Dinucleotide Cyclases

#2 | 2021-06-24

US20210187048A1

Human necessities

ONCOLYTIC RHABDOVIRUS

#3 | 2019-06-06

US20190169578A1

Chemistry; metallurgy

Methods and compositions for production of vaccina virus

#4 | 2019-03-07

US20190070280A1

Human necessities

ONCOLYTIC VIRUS AND CHECKPOINT INHIBITOR COMBINATION THERAPY

#5 | 2019-01-24

US20190022203A1

Human necessities

ONCOLYTIC VIRUS AND CHECKPOINT INHIBITOR COMBINATION THERAPY

#6 | 2018-12-27

US20180369303A1

Human necessities

ONCOLYTIC RHABDOVIRUS

#7 | 2018-08-02

US20180214538A1

Human necessities

Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

#8 | 2018-03-08

US20180064805A1

Human necessities

Method of Vaccination Comprising a Histone Deacetylase Inhibitor

#9 | 2017-10-19

US20170298324A1

Chemistry; metallurgy

Methods and compositions for production of vaccinia virus

#10 | 2017-06-15

US20170165305A1

Human necessities

ONCOLYTIC RHABDOVIRUS

#11 | 2015-07-23

US20150202240A1

Human necessities

Compositions and methods for enhancing virus efficacy

#12 | 2015-02-05

US20150037355A1

Human necessities

Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

#13 | 2014-07-10

US20140193458A1

Human necessities

Method of vaccination comprising a histone deacetylase inhibitor

#14 | 2014-06-12

US20140162342A1

Chemistry; metallurgy

Methods and compositions for production of vaccinia virus

#15 | 2014-01-09

US20140010787A1

Human necessities

Oncolytic rhabdovirus

#16 | 2012-05-31

US20120134963A1

Human necessities

Compositions and methods for enhancing virus efficacy

#17 | 2011-03-03

US20110052539A1

Human necessities

Oncolytic rhabdovirus

#18 | 2009-06-04

US20090144077A1

Method and system for determining exposures presented by an orchestrated process

InventorID:

604880 ⎘